Home/Filings/4/0000874716-25-000026
4//SEC Filing

Lane Michael 4

Accession 0000874716-25-000026

CIK 0000874716other

Filed

Feb 17, 7:00 PM ET

Accepted

Feb 18, 9:43 PM ET

Size

26.6 KB

Accession

0000874716-25-000026

Insider Transaction Report

Form 4
Period: 2025-02-13
Lane Michael
Executive Vice President
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-14+1606,650.235 total
  • Exercise/Conversion

    Common Stock

    2025-02-14+2046,854.235 total
  • Exercise/Conversion

    Common Stock

    2025-02-14+2207,074.235 total
  • Exercise/Conversion

    Common Stock

    2025-02-14+3017,375.235 total
  • Tax Payment

    Common Stock

    2025-02-14$444.53/sh272$120,9127,103.235 total
  • Award

    Non-Qualified Stock Option (right-to-buy)

    2025-02-13+6,3206,320 total
    Exercise: $459.76Exp: 2035-02-12Common Stock (6,320 underlying)
  • Award

    Incentive Stock Option (right-to-buy)

    2025-02-13+217217 total
    Exercise: $459.76Exp: 2035-02-12Common Stock (217 underlying)
  • Award

    Restricted Stock Unit

    2025-02-13+1,4681,468 total
    Common Stock (1,468 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-141600 total
    Common Stock (160 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-14204204 total
    Common Stock (204 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-14220440 total
    Common Stock (220 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    2025-02-14301903 total
    Common Stock (301 underlying)
Holdings
  • Common Stock

    (indirect: By Spouse)
    592
Footnotes (9)
  • [F1]Includes a total of 47 shares purchased under the Issuer Employee Stock Purchase Plan on March 29, 2024, June 28, 2024, September 30, 2024 and December 31, 2024.
  • [F2]Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.
  • [F3]Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026.
  • [F4]Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029.
  • [F5]Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in four annual installments, beginning February 14, 2026.
  • [F6]Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2022.
  • [F7]Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023.
  • [F8]Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.
  • [F9]Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.

Issuer

IDEXX LABORATORIES INC /DE

CIK 0000874716

Entity typeother

Related Parties

1
  • filerCIK 0001740689

Filing Metadata

Form type
4
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 9:43 PM ET
Size
26.6 KB